| 0.975 -0.035 (-3.47%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.48  |
1-year : | 1.75 |
| Resists | First : | 1.27 |
Second : | 1.5 |
| Pivot price | 1.11 |
|||
| Supports | First : | 0.89 |
Second : | 0.74 |
| MAs | MA(5) : | 1.04 |
MA(20) : | 1.16 |
| MA(100) : | 0.88 |
MA(250) : | 0.93 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 12.3 |
D(3) : | 15.4 |
| RSI | RSI(14): 42.1 |
|||
| 52-week | High : | 1.55 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TELA ] has closed above bottom band by 5.7%. Bollinger Bands are 4.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.12 - 1.12 | 1.12 - 1.13 |
| Low: | 0.95 - 0.96 | 0.96 - 0.96 |
| Close: | 0.96 - 0.97 | 0.97 - 0.99 |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Tue, 06 Oct 2026
TELA Bio regains Nasdaq Global Market minimum bid price compliance - TradingView
Mon, 05 Oct 2026
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement - GlobeNewswire
Mon, 05 Oct 2026
TELA Bio Receives FDA 510(k) Clearance for Liora Monofilament Scaffold, Expanding Soft-Tissue Reconstruction Portfolio - Quiver Quantitative
Mon, 05 Oct 2026
The FDA cleared a surgical mesh designed to be fully absorbed by the body. - Stock Titan
Wed, 16 Sep 2026
TELA Bio (TELA) director adds to stake in open-market buys - Stock Titan
Mon, 31 Aug 2026
TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 45 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 7.1 (%) |
| Held by Institutions | 63.2 (%) |
| Shares Short | 469 (K) |
| Shares Short P.Month | 385 (K) |
| EPS | -0.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.35 |
| Profit Margin | -51.6 % |
| Operating Margin | -48.2 % |
| Return on Assets (ttm) | -33.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -4.5 % |
| Gross Profit (p.s.) | 1.2 |
| Sales Per Share | 1.77 |
| EBITDA (p.s.) | -0.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -1.27 |
| PEG Ratio | 0 |
| Price to Book value | -2.79 |
| Price to Sales | 0.55 |
| Price to Cash Flow | -1.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|